S. Tejpar

Discipline

Sciences de l'information et de la communication (1) Histoire, Philosophie et Sociologie des sciences (1)

Type de document

Articles (17) Recensions (2)

Co-auteur

Date

Source

Mot-clé

Colon (Anatomy)--Cancer (15) Treatment (11) procès (10) survie (10) Survival (10) Prognosis (10) Patients (10) Human beings (10) Prognosis (10) Patients (10) Rectum--Cancer (9) Theater (9) Drama (9) Acting (9) analyse (8) gène (8) Analysis (8) maladie (7) Value (7) Tumors (7) Cancer (7) cohorte (7) maladie (7) mutation (6) Chemotherapy (6) Genes (6) Gene expression (6) Expression (6) Chemotherapy (6) Mutation (6)

Documents écrit par S. Tejpar (17) | parle de S. Tejpar (0)

Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGFβ.
M. Germann et al. (9 janv. 2020)
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.
R. Dienstmann et al. (1 mai 2017)
Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data.
I.K. Buhl et al. (2016)
DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.
S.B. Nygård et al. (2016)
Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance.
N.F. Jensen et al. (2015)
Response.
M. Delorenzi et al. (2015)
Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial?.
D. Klingbiel et al. (2015)
The consensus molecular subtypes of colorectal cancer.
J. Guinney et al. (2015)
miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.
J.V. Schou et al. (2014)
Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
A.F. Di Narzo et al. (2014)
Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer.
V. Popovici et al. (27 sept. 2013)
Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer.
E. Budinska et al. (2013)
A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations.
T. Xie et al. (2012)
A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency.
S. Tian et al. (2012)
Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle.
S. Tejpar et al. (2011)
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.
S. Tejpar et al. (2010)
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
J.H. van Krieken et al. (2008)